Phase 2/3 Study of Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS.
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Cytarabine (Primary) ; Filgrastim (Primary) ; Omacetaxine mepesuccinate (Primary) ; Decitabine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHG DAC001
- 02 Sep 2011 Planned end date changed from Aug 2013 to Sep 2013 as reported by ClinicalTrials.gov.
- 02 Sep 2011 Planned initiation date changed from Aug 2011 to Sep 2011 as reported by ClinicalTrials.gov.
- 18 Aug 2011 New trial record